Clinical Effects Of Recombinant Human Thrombopoietin In The Treatment Of Chemotherapy-Induced Thrombocytopenia In Lung Cancer Patients

Background:Malignant tumor patient after chemotherapy, often have different degrees of platelets (PLT) reduce。Patients may occur bleeding tendency, prevent and cure tough, often influence the implementation of chemotherapy. Infusion PLT levitation liquid easily induced resistance own produced PLT antibody, cause infusion invalid or blood transfusion complications. Recombinant human thrombopoietin(rhTPO) is the effective drug for treatment PLT decrease, In foreign countries has been approved as treatment drug for PLT decrease caused by chemotherapy. Research shows that rhTPO can increase in medium and severely bone marrow inhibit platelet number of patients, promote platelet recovery. We have collected 41 NSCLC patients who appears different degree thrombocytopenia after chemotherapy, giving rhTPO for treatment, to eviluate the clinical efficacy and safety.Material and method:Collecting 41 patients from 2007.01 to 2009.12, who had been diagnosed by pathology as non-small cell lung cancer (NSCLC), of which the male number is 25 and the female number is 16. The age is from 38 to 75 years, mean age is 61 years old. All patients PS scores are more than two points.According to UICC TNM standard, I period 2 cases (4.9 percent),Ⅱperiod 5 cases (12.2 percent), III period 14 cases (34.1 percent), IV period 20 cases (48.8 percent)。Selected patients with liver and kidney function all normal, No serious cardiopulmonary functional obstacle, No accompanied by severe acute infection and active bleeding history.10 patients is for the first treatment and 31 patients have chemotherapy history。Chemotherapy regimens are two drugs combination which contains platinum。Results:The duration of the chemotherapy-induced thrombecytopenia wag significantly shorter in the mild group than that in the moderate and severe groups(P<0.01). After administration of rhTPO, the time of declined platelet count beginning to recover was also significantly shorter in the mild group than that in the moderate and severe groups(P<0.01). There was a statistically significant difference in platelet transfusion needed among the three groups(P<0.01). However, no significant difference was found among the three groups in the time of rhTPO treatment(P>0.05)and platelet count improvement(P>0.05)。Conclusion:Recombinant human thrombopoietin can be effectively and safely administered to deal with gradeⅢ,Ⅳchemotherapy-induced thrombopoietin lung cancer patients with mild adverse effects。...